Biotechnology News and Research

RSS

Mental health services, tobacco control programs must work together to encourage smoking cessation

Persons with mental illness account for more than one-third of adult smokers in the United States and despite a decline in tobacco use during the past five decades, there has been no change in the smoking rate for patients with poor mental health.

7 Nov 2013

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

ImmunGene, Inc., a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer, today announced it has secured $9 million in a milestone-based Series A financing from Ally Bridge Group. Previous investments in the Company were converted into Series A preferred stock. ImmunGene will use the capital to advance its early-stage development products to IND-enabling studies.

7 Nov 2013

Patrys receives FDA Orphan Medicinal Product Designation for PAT-SM6

Patrys Limited, a clinical stage biotechnology company, has received confirmation of Orphan Medicinal Product Designation for its lead anti-cancer product PAT-SM6, from the USA Food and Drugs Administration.

7 Nov 2013

PDL BioPharma closes financing transaction with Durata Therapeutics

PDL BioPharma, Inc. announced today that it closed a financing transaction with Durata Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.

6 Nov 2013

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.

6 Nov 2013

ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, today announced the start of clinical testing with its EGFR-targeting ADC, IMGN289.

6 Nov 2013

Furiex reports financial and operating results for third quarter 2013

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2013.

6 Nov 2013

ImmunoGen decides to stop IMGN901 Phase II SCLC study

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, announced today the decision to stop the IMGN901 Phase II SCLC study, following the recommendation of the trial's independent Data Monitoring Committee.

6 Nov 2013

FDA grants Orphan Drug Designation to Advaxis' ADXS-HPV for HPV-associated head and neck cancer

Advaxis, Inc.,, a leader in developing the next generation of cancer immunotherapies, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated head and neck cancer.

6 Nov 2013

Life Technologies revenue for third quarter increases 3% to $936

Life Technologies Corporation (NASDAQ: LIFE) today announced results for its third quarter ended September 30, 2013. Revenue for the third quarter was $936 million, an increase of 3 percent over the $911 million reported for the third quarter of 2012.

5 Nov 2013

BioMed Realty Trust's total revenues up by 18.4% in third quarter 2013

BioMed Realty Trust, Inc., the leading provider of real estate to the life science industry, today announced financial results for the third quarter ended September 30, 2013.

5 Nov 2013

Research findings could offer new insights into how defective cells can multiply in diseases

A rudimentary form of life that is found in some of the harshest environments on earth is able to sidestep normal replication processes and reproduce by the back door, researchers at The University of Nottingham have found.

5 Nov 2013

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Biothera announced today top-line results from its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) that evaluated its immunotherapeutic drug candidate, Imprime PGG®, with cetuximab (Erbitux®), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapy combination alone.

5 Nov 2013

Nanomedicine Award winners officially announced at BIO-Europe conference

The winners of the first ever Nanomedicine Award were officially announced during the Nanomedicine Panel at BIO-Europe conference in Vienna, November 4th 2013. The Award review Board agreed to distinguish two projects in two different categories: The winners are Endomagnetics Ltd in the nanodiagnostic category and the I-CARE project from Linköping University in the regenerative medicine category.

4 Nov 2013

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.

4 Nov 2013

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, announced that its most advanced ImmTAC drug, IMCgp100 for the treatment of late stage melanoma, has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed. The company has now initiated a Phase IIa clinical trial in the UK and USA.

1 Nov 2013

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Crown serves pharmaceutical companies and biotech companies. We have two areas of focus: oncology and metabolic diseases. In the oncology space we focus on pre-clinical services. Essentially, we have all the tools to help our customers move from target discovery, target validation, to a clinical candidate.

31 Oct 2013

Biotechnology News and Research

Mental health services, tobacco control programs must work together to encourage smoking cessation

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

Patrys receives FDA Orphan Medicinal Product Designation for PAT-SM6

PDL BioPharma closes financing transaction with Durata Therapeutics

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

Furiex reports financial and operating results for third quarter 2013

ImmunoGen decides to stop IMGN901 Phase II SCLC study

FDA grants Orphan Drug Designation to Advaxis' ADXS-HPV for HPV-associated head and neck cancer

Life Technologies revenue for third quarter increases 3% to $936

BioMed Realty Trust's total revenues up by 18.4% in third quarter 2013

Research findings could offer new insights into how defective cells can multiply in diseases

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Nanomedicine Award winners officially announced at BIO-Europe conference

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

VG Life Sciences' peptide awarded US patent for HIV treatment

Nanosonics named healthcare industry’s Company of the Year for 2013

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News